Terms: = Uterine cancer AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Prognosis
7 results:
1. prognosis and adjuvant chemotherapy for patients with malignant peritoneal cytology in early-stage non-endometrioid endometrial cancer.
Tang X; Li N; Hu Y
Eur J Surg Oncol; 2023 Nov; 49(11):107071. PubMed ID: 37708662
[TBL] [Abstract] [Full Text] [Related]
2. Identification of HOXB9 to predict prognosis of endometrial cancer based on comprehensive bioinformatics analysis.
Xu Y; Zhang M; Shi Q; Cheng X; Du R; Li C; Zhang Y
Eur J Med Res; 2023 Feb; 28(1):79. PubMed ID: 36803556
[TBL] [Abstract] [Full Text] [Related]
3. Preoperative leukocytosis correlates with unfavorable pathological and survival outcomes in endometrial carcinoma: A systematic review and meta-analysis.
Abu-Zaid A; Alomar O; Baradwan S; Abuzaid M; Alshahrani MS; Allam HS; Alqarni SMS; Nazer A; Salem H; Al-Badawi IA
Eur J Obstet Gynecol Reprod Biol; 2021 Sep; 264():88-96. PubMed ID: 34298450
[TBL] [Abstract] [Full Text] [Related]
4. prognosis of bulky pTIIB cervical cancer treated by radical hysterectomy comparing adenocarcinoma with squamous cell carcinoma using propensity score matching.
Okadome M; Nagayama R; Shimokawa M; Sonoda K; Shimamoto K; Saito T
Int J Gynaecol Obstet; 2021 Apr; 153(1):56-63. PubMed ID: 33119174
[TBL] [Abstract] [Full Text] [Related]
5. Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithm.
Multinu F; Ducie JA; Eriksson AGZ; Schlappe BA; Cliby WA; Glaser GE; Grassi T; Keeney GL; Weaver AL; Abu-Rustum NR; Leitao MM; Mariani A
Gynecol Oncol; 2019 Nov; 155(2):177-185. PubMed ID: 31604668
[TBL] [Abstract] [Full Text] [Related]
6. Recurrence patterns after radical hysterectomy in stage IB1-IIA cervical.
Sittidilokratna K; Cheewakriangkrai C; Khunamornpong S; Siriaunkgul S
Asian Pac J Cancer Prev; 2010; 11(2):499-502. PubMed ID: 20843140
[TBL] [Abstract] [Full Text] [Related]
7. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract] [Full Text] [Related]
